A meta-analysis of ferric carboxymaltose versus other intravenous iron preparations for the management of iron deficiency anemia during pregnancy.


Journal

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia
ISSN: 1806-9339
Titre abrégé: Rev Bras Ginecol Obstet
Pays: Brazil
ID NLM: 9214757

Informations de publication

Date de publication:
2024
Historique:
received: 12 04 2023
accepted: 08 08 2023
medline: 20 5 2024
pubmed: 20 5 2024
entrez: 20 5 2024
Statut: epublish

Résumé

We conducted a meta-analysis of randomized clinical trials evaluating the clinical effects of ferric carboxymaltose therapy compared to other intravenous iron in improving hemoglobin and serum ferritin in pregnant women. We also assessed the safety of ferric carboxymaltose vs. other intravenous iron. EMBASE, PubMed, and Web of Science were searched for trials related to ferric carboxymaltose in pregnant women, published between 2005 and 2021. We also reviewed articles from google scholar. The keywords "ferric carboxymaltose," "FCM," "intravenous," "randomized," "pregnancy," "quality of life," and "neonatal outcomes" were used to search the literature. The search was limited to pregnant women. Studies related to ferric carboxymaltose in pregnancy were scanned. Observational studies, review articles, and case reports were excluded. Randomized studies in pregnant women involving ferric carboxymaltose and other intravenous iron formulations were shortlisted. Of 256 studies, nine randomized control trials were selected. Two reviewers independently extracted data from nine selected trials. The final effect size for increase in hemoglobin after treatment was significant for ferric carboxymaltose vs. iron sucrose/iron polymaltose (standard mean difference 0.89g/dl [95% confidence interval 0.27,1.51]). The final effect size for the increase in ferritin after treatment was more for ferric carboxymaltose vs. iron sucrose/iron polymaltose (standard mean difference 22.53µg/L [-7.26, 52.33]). No serious adverse events were reported with ferric carboxymaltose or other intravenous iron. Ferric carboxymaltose demonstrated better efficacy than other intravenous iron in increasing hemoglobin and ferritin levels in treating iron deficiency anemia in pregnant women.

Identifiants

pubmed: 38765534
doi: 10.61622/rbgo/2024AO21
pii: rbgo/2024AO21
pmc: PMC11075392
pii:
doi:

Substances chimiques

ferric carboxymaltose 0

Types de publication

Journal Article Meta-Analysis Comparative Study Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Federação Brasileira de Ginecologia e Obstetrícia. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts to interest: none to declare.

Auteurs

Sanjay Gupte (S)

Gupte Hospital & Center for Research in Reproduction Department of Obstetrics and Gynecology India Department of Obstetrics and Gynecology, Gupte Hospital & Center for Research in Reproduction, India.

Ashis Mukhopadhyay (A)

CSS College of Obstetrics Gynae. & Child health Department of Gynecology Kolkata India Department of Gynecology, CSS College of Obstetrics, Gynae. & Child health, Kolkata, India.

Manju Puri (M)

Lady Hardinge Medical College Department of Obstetrics and Gynecology New Delhi India Department of Obstetrics and Gynecology, Lady Hardinge Medical College, New Delhi, India.

P M Gopinath (PM)

Institute of Obg & IVF SIMS Hospital Department of Obstetrics and Gynecology VadapalaniChennai India Department of Obstetrics and Gynecology, Institute of Obg & IVF SIMS Hospital, Vadapalani, Chennai, India.

Reena Wani (R)

HBTMC & Dr RN Cooper Hospital Department of Obstetrics and Gynecology Mumbai India Department of Obstetrics and Gynecology, HBTMC & Dr RN Cooper Hospital, Mumbai, India.

J B Sharma (JB)

Department of Obstetrics and Gynecology AIIMSNew Delhi India Department of Obstetrics and Gynecology, AIIMS, New Delhi, India.

Onkar C Swami (OC)

Emcure Pharmaceuticals Ltd Pune India Emcure Pharmaceuticals Ltd, Pune, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH